Emmaus Life Sciences Inc (Emmaus) is a commercial-stage biopharmaceutical company involved in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases such as sickle cell disease. The company commercial product, Endari (prescription grade L-glutamine oral powder) has received marketing approval from the US Food and Drug Administration (FDA), intended to reduce the acute complications of sickle cell disease (“SCD”) in adult and and children 5 years and older.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Emmaus’ R&D activities primarily involve expenditures for the development of the company's products and product candidates. This includes contract research, payroll-related expenses, and other related supplies. The company also incurs expenses for new products and technologies, which primarily consist of fees paid to contract research organizations that conduct clinical trials of the company's product candidates, study site payments, consultant fees, and other related costs. The company’s pipeline product candidates include ELS004 being developed for the treatment of diverticulosis, is currently in Phase I clinical trials; ELS005 for the treatment of blood cancer is in Preclinical Phase; ELS003, a research tool to measure transmittance of cell sheet, is in Preclinical trials; and ELS002, being developed for the treatment of osteoarthritis, is currently in Preclinical trials. In FY2023, the company spent US$1.2 million on its R&D activities, which as a percentage of revenue stood at 4.1%.